Management of rheumatoid arthritis: A primary care perspective—CME Information

Continue to Article

CME Test
FREE 1.5 CME Credits

Release Date: October 1, 2007

Expiration Date: September 30, 2008

Learning Objectives

At the conclusion of this activity, participants should be better able to:

• Identify and address barriers to diagnosis and improved outcomes for rheumatoid arthritis (RA) in the primary care setting

• Demonstrate the importance of an early and accurate diagnosis of RA

• Examine appropriate RA patient management through a collaborative team approach

• Describe the monitoring of potential adverse events and benefits of primary care management of RA patients

Accreditation Statement

The Chatham Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The Chatham Institute designates this medical activity for a maximum of 1.5 AMA PRA Category 1 Credits^™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The Chatham Institute is an approved provider of continuing nursing education by the New Jersey State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. The Chatham Institute is approved by the California Board of Registered Nursing, Provider Number CEP 12433. This activity is approved for 1.5 contact hours.

Disclaimer

Accreditation refers to educational content only and does not imply endorsement of products by the New Jersey State Nurses Association, American Nurses Credentialing Center, California Board of Registered Nursing, or the Chatham Institute.

Target Audience

This newsletter has been designed to meet the educational needs of primary care clinicians who are interested in learning about the diagnosis and management of rheumatoid arthritis.

Disclosures

It is the policy of The Chatham Institute to ensure balance, independence, objectivity, and scientific rigor in all of its educational programs. All faculty, planners, and managers who affect the content of medical education activities sponsored by The Chatham Institute are required to disclose any real or apparent conflict of interest related to the activity. Faculty, planners, and managers not complying with the disclosure policy will not be permitted to participate in this activity. Disclosure information is provided below.

Program faculty and planners have disclosed the financial relationships with commercial interests cited below. All program content has been peer reviewed for balance and any potential bias. The conflict of interest resolution process aims to ensure that financial relationships with commercial interests and resultant loyalties do not supersede the public interest in the design and delivery of continuing medical education activities for the profession.

• David S. Kountz, MD
  Consultant Fees: Novartis Pharmaceuticals Corporation, Pfizer Inc, Merck & Co., Inc.

• Joan Marie Von Feldt, MD
  Consultant Fees: Genentech, Inc., Amgen Inc.

• Daniel Duch, PhD
  Scientific Director, The Chatham Institute No real or apparent conflicts to report

Acknowledgement

This CME activity was supported by educational grants from Abbott Laboratories, Amgen Inc., Centocor, Inc., and Wyeth Pharmaceuticals.

This material has been submitted by The Chatham Institute. It has been edited and peer reviewed by The Journal of Family Practice.

Continue to Article